Tags

Type your tag names separated by a space and hit enter

Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant.
medRxiv. 2021 Feb 05M

Abstract

Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS-CoV-2 infection and can last for several months. Similarly, the messenger RNA vaccine, mRNA-1273, generates serum neutralizing antibodies that are detected through at least day 119. However, the recent emergence of the B.1.1.7 variant has raised significant concerns about the breadth of these neutralizing antibody responses. In this study, we used a live virus neutralization assay to compare the neutralization potency of sera from infected and vaccinated individuals against a panel of SARS-CoV-2 variants, including SARS-CoV-2 B.1.1.7. We found that both infection- and vaccine-induced antibodies were effective at neutralizing the SARS-CoV-2 B.1.1.7 variant. These findings support the notion that in the context of the UK variant, vaccine-induced immunity can provide protection against COVID-19. As additional SARS-CoV-2 viral variants continue to emerge, it is crucial to monitor their impact on neutralizing antibody responses following infection and vaccination.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Preprint

Language

eng

PubMed ID

33564782

Citation

Edara, Venkata Viswanadh, et al. "Infection and mRNA-1273 Vaccine Antibodies Neutralize SARS-CoV-2 UK Variant." MedRxiv : the Preprint Server for Health Sciences, 2021.
Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021.
Edara, V. V., Floyd, K., Lai, L., Gardner, M., Hudson, W., Piantadosi, A., Waggoner, J. J., Babiker, A., Ahmed, R., Xie, X., Lokugamage, K., Menachery, V., Shi, P. Y., & Suthar, M. S. (2021). Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. MedRxiv : the Preprint Server for Health Sciences. https://doi.org/10.1101/2021.02.02.21250799
Edara VV, et al. Infection and mRNA-1273 Vaccine Antibodies Neutralize SARS-CoV-2 UK Variant. medRxiv. 2021 Feb 5; PubMed PMID: 33564782.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. AU - Edara,Venkata Viswanadh, AU - Floyd,Katharine, AU - Lai,Lilin, AU - Gardner,Meredith, AU - Hudson,William, AU - Piantadosi,Anne, AU - Waggoner,Jesse J, AU - Babiker,Ahmed, AU - Ahmed,Rafi, AU - Xie,Xuping, AU - Lokugamage,Kumari, AU - Menachery,Vineet, AU - Shi,Pei-Yong, AU - Suthar,Mehul S, Y1 - 2021/02/05/ PY - 2021/2/10/entrez PY - 2021/2/11/pubmed PY - 2021/2/11/medline JF - medRxiv : the preprint server for health sciences JO - medRxiv N2 - Antibody responses against the SARS-CoV-2 Spike protein correlate with protection against COVID-19. Serum neutralizing antibodies appear early after symptom onset following SARS-CoV-2 infection and can last for several months. Similarly, the messenger RNA vaccine, mRNA-1273, generates serum neutralizing antibodies that are detected through at least day 119. However, the recent emergence of the B.1.1.7 variant has raised significant concerns about the breadth of these neutralizing antibody responses. In this study, we used a live virus neutralization assay to compare the neutralization potency of sera from infected and vaccinated individuals against a panel of SARS-CoV-2 variants, including SARS-CoV-2 B.1.1.7. We found that both infection- and vaccine-induced antibodies were effective at neutralizing the SARS-CoV-2 B.1.1.7 variant. These findings support the notion that in the context of the UK variant, vaccine-induced immunity can provide protection against COVID-19. As additional SARS-CoV-2 viral variants continue to emerge, it is crucial to monitor their impact on neutralizing antibody responses following infection and vaccination. UR - https://www.unboundmedicine.com/medline/citation/33564782/Infection_and_mRNA_1273_vaccine_antibodies_neutralize_SARS_CoV_2_UK_variant_ L2 - https://doi.org/10.1101/2021.02.02.21250799 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.